Chen X, Wu Y, Dong H, Zhang CY, Zhang Y. Platinum-based agents for individualized cancer treatment. Curr Mol Med. 2013;13(10):1603–12.
Article
CAS
PubMed
Google Scholar
Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103–24.
Article
CAS
PubMed
Google Scholar
Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–84.
Article
CAS
PubMed
Google Scholar
Tao K, Yin Y, Shen Q, Chen Y, Li R, Chang W, et al. Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells. Biomed Rep. 2016;4(3):365–8.
Article
PubMed
PubMed Central
Google Scholar
Baharuddin P, Satar N, Fakiruddin KS, Zakaria N, Lim MN, Yusoff NM, et al. Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines. Oncol Rep. 2016;35(1):13–25.
Article
CAS
PubMed
Google Scholar
Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2003;2:1.
Article
PubMed
PubMed Central
Google Scholar
Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40.
Article
CAS
PubMed
Google Scholar
Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res. 2003;63(23):8330–7.
CAS
PubMed
Google Scholar
Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–2.
Article
CAS
PubMed
Google Scholar
Houles T, Roux PP. Defining the role of the RSK isoforms in cancer. Seminars in cancer biology. Cambridge: Academic Press; 2017.
Google Scholar
Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441(2):553–69.
Article
CAS
PubMed
Google Scholar
Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, et al. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Oncogene. 2013;32(24):2917–26.
Article
CAS
PubMed
Google Scholar
Eisinger-Mathason TS, Andrade J, Groehler AL, Clark DE, Muratore-Schroeder TL, Pasic L, et al. Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Mol Cell. 2008;31(5):722–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Abdulrahman N, Jaballah M, Poomakkoth N, Riaz S, Abdelaziz S, Issa A, et al. Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin. Mol Cell Biochem. 2016;418(1):21–9.
Article
CAS
PubMed
Google Scholar
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78.
Article
CAS
PubMed
Google Scholar
Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467–98.
Article
CAS
PubMed
Google Scholar
Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, et al. Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 2014;44(3):923–33.
Article
CAS
PubMed
Google Scholar
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salvesen GS, Abrams JM. Caspase activation—stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene. 2004;23(16):2774–84.
Article
CAS
PubMed
Google Scholar
Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17(25):3237–45.
Article
PubMed
Google Scholar
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995;14(22):5579–88.
CAS
PubMed
PubMed Central
Google Scholar
Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70(4):1390–4.
Article
CAS
PubMed
Google Scholar
Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 2006;66(22):10944–52.
Article
CAS
PubMed
Google Scholar
Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-l-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006;53(3):278–86.
Article
CAS
PubMed
Google Scholar
Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460–4.
Article
CAS
PubMed
Google Scholar
dos Santos NA, Martins NM, Curti C, Pires Bianchi Mde L, dos Santos AC. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem Biol Interact. 2007;170(3):177–86.
Article
PubMed
CAS
Google Scholar
Li S, Li C, Jin S, Liu J, Xue X, Eltahan AS, et al. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. Biomaterials. 2017;144:119–29.
Article
CAS
PubMed
Google Scholar
Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes-a review. Anticancer Drugs. 2000;11(4):225–36.
Article
CAS
PubMed
Google Scholar
Ma J, Salamoun J, Wipf P, Edwards R, Van Houten B, Qian W. Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget. 2018;9(5):6042–54.
Article
PubMed
Google Scholar
Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, et al. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol. 2013;49(2):241–50.
Article
CAS
PubMed
Google Scholar
Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol. 1999;10(12):1457–60.
Article
CAS
PubMed
Google Scholar
Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Panopoulos C, Chrissohoou M, et al. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer. Breast. 2005;14(2):136–41.
Article
CAS
PubMed
Google Scholar
Lee MA, Woo IS, Kang J-H, Hong YS, Lee KS. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol. 2004;34(9):547–50.
Article
PubMed
Google Scholar
Apostolou P, Toloudi M, Chatziioannou M, Ioannou E, Knocke DR, Nester J, et al. Anvirzel in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines. BMC Pharmacol Toxicol. 2013;14:18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Byun JM, Jeong DH, Lee DS, Kim JR, Park SG, Kang MS, et al. Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer. Oncol Rep. 2013;29(4):1540–6.
Article
CAS
PubMed
Google Scholar
Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999;85(2):295–301.
Article
CAS
PubMed
Google Scholar
Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, Ivy SP. Phase I trial of triapine–cisplatin–paclitaxel chemotherapy for advanced stage or metastatic solid tumor cancers. Front Oncol. 2017;7:62.
PubMed
PubMed Central
Google Scholar
Wu H, Jin H, Wang C, Zhang Z, Ruan H, Sun L, et al. Synergistic cisplatin/doxorubicin combination chemotherapy for multidrug-resistant cancer via polymeric nanogels targeting delivery. ACS Appl Mater Interfaces. 2017;9(11):9426–36.
Article
CAS
PubMed
Google Scholar
Shaaban S, Negm A, Ibrahim EE, Elrazak AA. Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. Oncol Rev. 2014;8(1):246.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, et al. Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 2013;119(18):3334–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee J, Kim HH, Ro SM, Yang JH. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. PLoS ONE. 2017;12(2):e0171605.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.
Article
PubMed
Google Scholar
Liu Y, Chen L, He X, Fan L, Yang G, Chen X, et al. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer. 2008;18(4):652–9.
Article
CAS
PubMed
Google Scholar
Kim JH, Jeong SJ, Kim B, Yun SM, Choi do Y, Kim SH. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 2012;52(2):244–52.
Article
CAS
PubMed
Google Scholar
Tseng CY, Lin CH, Wu LY, Wang JS, Chung MC, Chang JF, et al. Potential combinational anti-cancer therapy in non-small cell lung cancer with traditional Chinese medicine Sun-Bai-Pi extract and cisplatin. PLoS One. 2016;11(5):e0155469.
Article
PubMed
PubMed Central
CAS
Google Scholar
Dong J, Su S-Y, Wang M-Y, Zhan Z. Shenqi fuzheng, an injection concocted from chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res. 2010;29(1):137.
Article
PubMed
PubMed Central
Google Scholar
Plaimee P, Weerapreeyakul N, Barusrux S, Johns NP. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif. 2015;48(1):67–77.
Article
CAS
PubMed
Google Scholar
Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol. 2011;6(5):852–63.
Article
PubMed
Google Scholar
O’Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs. 2011;22(1):58–78.
Article
PubMed
CAS
Google Scholar
Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol. 2011;67(3):235–43.
Article
CAS
PubMed
Google Scholar
Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, et al. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis. Mol Med. 2011;17(7–8):635–45.
CAS
PubMed
PubMed Central
Google Scholar
Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, et al. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest. 2011;91(1):124–37.
Article
CAS
PubMed
Google Scholar
Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, et al. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest. 2009;89(10):1115–27.
Article
CAS
PubMed
Google Scholar
Yang Q, Zhang S, Kang M, Dong R, Zhao J. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. Oncol Rep. 2015;33(5):2537–44.
Article
CAS
PubMed
Google Scholar
Wang H, Sun R, Chi Z, Li S, Hao L. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-kappaB signaling pathway in human neuroblastoma SH-SY5Y cells. Mol Cell Biochem. 2017;433:1–2.
Article
CAS
PubMed
Google Scholar
Ji X, Wang Z, Sarkar FH, Gupta SV. Delta-tocotrienol augments cisplatin-induced suppression of non-small cell lung cancer cells via inhibition of the Notch-1 pathway. Anticancer Res. 2012;32(7):2647–55.
CAS
PubMed
Google Scholar
Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA, Santos L. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res. 2009;28:3.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004;93(1):143–50.
Article
CAS
PubMed
Google Scholar
Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther. 2008;7(6):1347–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model. Pharmacology. 2007;79(4):207–13.
Article
CAS
PubMed
Google Scholar
Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, et al. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs. 2010;28(4):413–20.
Article
CAS
PubMed
Google Scholar
Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer (Auckl). 2013;7:7–22.
CAS
PubMed
PubMed Central
Google Scholar
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005;4(1):25.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, et al. Dual targeting of mTOR activity with Torin2 potentiates anticancer effects of cisplatin in epithelial ovarian cancer. Mol Med. 2015;21:466–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(1):19–31.
Article
CAS
PubMed
Google Scholar
Ben-Levy R, Leighton IA, Doza YN, Attwood P, Morrice N, Marshall CJ, et al. Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J. 1995;14(23):5920–30.
CAS
PubMed
PubMed Central
Google Scholar
Bogoyevitch MA, Court NW. Counting on mitogen-activated protein kinases–ERKs 3, 4, 5, 6, 7 and 8. Cell Signal. 2004;16(12):1345–54.
Article
CAS
PubMed
Google Scholar
Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24(1):21–44.
Article
CAS
PubMed
Google Scholar
Qin X, Liu C, Zhou Y, Wang G. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk/MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand). 2010;56(Suppl):OL1366–72.
CAS
Google Scholar
Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275(50):39435–43.
Article
CAS
PubMed
Google Scholar
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 2002;63(8):1423–30.
Article
CAS
PubMed
Google Scholar
Nowak G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. J Biol Chem. 2002;277(45):43377–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 1999;274(44):31648–54.
Article
CAS
PubMed
Google Scholar
Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res. 1999;5(5):1007–14.
CAS
PubMed
Google Scholar
Basu A, Tu H. Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta. Biochem Biophys Res Commun. 2005;334(4):1068–73.
Article
CAS
PubMed
Google Scholar
DeHaan RD, Yazlovitskaya EM, Persons DL. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol. 2001;48(5):383–8.
Article
CAS
PubMed
Google Scholar
Jones EV, Dickman MJ, Whitmarsh AJ. Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J. 2007;405(3):617–23.
Article
CAS
PubMed
PubMed Central
Google Scholar
Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 2006;25(56):7381–90.
Article
CAS
PubMed
Google Scholar
Lafarga V, Cuadrado A, Nebreda AR. p18(Hamlet) mediates different p53-dependent responses to DNA-damage inducing agents. Cell Cycle. 2007;6(19):2319–22.
Article
CAS
PubMed
Google Scholar
Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 2003;278(21):19245–56.
Article
CAS
PubMed
Google Scholar
Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer. 2004;112(6):974–85.
Article
CAS
PubMed
Google Scholar
Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR. Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med. 2013;5(11):1759–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rodríguez-García ME, Quiroga AG, Castro J, Ortiz A, Aller P, Mata F. Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. Toxicol Sci. 2009;111(2):413–23.
Article
PubMed
CAS
Google Scholar
Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L, et al. Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. Cancer Lett. 2014;347(2):212–24.
Article
CAS
PubMed
Google Scholar
Lowery MA, O’Reilly EM, Harding JJ, Yu KH, Cercek A, Hollywood E, et al. A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC). J Clin Oncol. 2017;35((4_suppl)):290.
Article
Google Scholar
Kim HS, Kim SJ, Bae J, Wang Y, Park SY, Min YS, et al. The p90rsk-mediated signaling of ethanol-induced cell proliferation in HepG2 cell line. Korean J Physiol Pharmacol. 2016;20(6):595–603.
Article
PubMed
PubMed Central
Google Scholar
Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective targeting of RSK isoforms in cancer. Trends Cancer. 2017;3(4):302–12.
Article
PubMed
Google Scholar
Eisinger-Mathason TS, Andrade J, Lannigan DA. RSK in tumorigenesis: connections to steroid signaling. Steroids. 2010;75(3):191–202.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lara R, Mauri FA, Taylor H, Derua R, Shia A, Gray C, et al. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis. Oncogene. 2011;30(32):3513–21.
Article
CAS
PubMed
Google Scholar
Kang S, Elf S, Lythgoe K, Hitosugi T, Taunton J, Zhou W, et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest. 2010;120(4):1165–77.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007;12(3):201–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005;65(3):1027–34.
CAS
PubMed
Google Scholar
Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res. 2005;65(8):3108–16.
Article
CAS
PubMed
Google Scholar
Arechavaleta-Velasco F, Zeferino-Toquero M, Estrada-Moscoso I, Imani-Razavi FS, Olivares A, Perez-Juarez CE, et al. Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines. Med Oncol. 2016;33(2):11.
Article
PubMed
CAS
Google Scholar
Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, et al. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. Mol Cancer Ther. 2012;11(12):2600–9.
Article
CAS
PubMed
Google Scholar
van Jaarsveld MTM, Blijdorp ICJ, Boersma AWM, Pothof J, Mathijssen RHJ, Verweij J, et al. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. Eur J Cancer. 2013;49(2):345–51.
Article
PubMed
CAS
Google Scholar
Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747–58.
Article
CAS
PubMed
Google Scholar
Zeniou M, Ding T, Trivier E, Hanauer A. Expression analysis of RSK gene family members: the RSK2 gene, mutated in Coffin–Lowry syndrome, is prominently expressed in brain structures essential for cognitive function and learning. Hum Mol Genet. 2002;11(23):2929–40.
Article
CAS
PubMed
Google Scholar
Dummler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, et al. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem. 2005;280(14):13304–14.
Article
PubMed
CAS
Google Scholar
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21(17):3194–200.
Article
CAS
PubMed
Google Scholar
Kano Y, Akutsu M, Suzuki K, Yoshida M. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leuk Res. 1993;17(2):113–9.
Article
CAS
PubMed
Google Scholar
Perez EA. Carboplatin in combination therapy for metastatic breast cancer. Oncologist. 2004;9(5):518–27.
Article
CAS
PubMed
Google Scholar
Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, et al. Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death Differ. 2016;24:300.
Article
PubMed
PubMed Central
CAS
Google Scholar
Poore B, Arnold A. Carboplatin is synergistic with MAPK inhibitors trametinib and everolimus in low grade glioma models. Neuro Oncol. 2017;19((suppl_4)):iv36.
Article
Google Scholar
Archer VR, Billingham LJ, Cullen MH. Palliative chemotherapy: no longer a contradiction in terms. Oncologist. 1999;4(6):470–7.
CAS
PubMed
Google Scholar